ScoreHaematology

IPI and revised IPI (R-IPI) in diffuse large B-cell lymphoma

Groups the five IPI factors into three prognostic categories adapted to the rituximab era.

Updated 31 October 2026

When to use it

Patients with DLBCL at diagnosis treated with R-CHOP, to estimate survival and stratify trials.

What it needs

  • Age > 60 yearsYes or no
  • Serum LDH above the upper limit of normalYes or no
  • ECOG ≥ 2Yes or no
  • Ann Arbor stage III–IVYes or no
  • More than 1 extranodal siteYes or no

The points for each answer and the automatic total are in the app.

How to interpret it

IPI risk factors
ResultInterpretation
≤ 1Classic IPI: low risk (0–1)
2Classic IPI: low-intermediate risk (2)
3Classic IPI: high-intermediate risk (3)
≥ 4Classic IPI: high risk (4–5)

In the app it also calculates: R-IPI group.

Practical tip

With rituximab, the classic IPI no longer identifies a group with < 50% survival; R-IPI better separates those with a very good outlook.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top